Louise Rodino-Klapac is a corporate insider at Sarepta Therapeutics, Inc. (SRPT). Rodino-Klapac has reported 10 insider filings with the SEC since 2024. The most recent filing was in March 2026.
Every role Louise Rodino-Klapac has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Sarepta Therapeutics, Inc. (SRPT)8 filingsUpdated Aug 31, 2026
Louise Rodino-Klapac is President, R&D and Tech Ops of Sarepta Therapeutics, Inc. (SRPT). 8 SEC Form 4 filings on record going back to 2024, most recently on 14 March 2026.
Every recent SEC Form 4 transaction Louise Rodino-Klapac has reported, most recent first.
InsiderAlpha's records for Louise Rodino-Klapac go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Louise Rodino-Klapac files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Louise Rodino-Klapac is a corporate insider, tracked as President, R&D and Tech Ops of Sarepta Therapeutics, Inc. (SRPT). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 14 March 2026, one of 8 filings going back to 2024.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$SRPT Sarepta Therapeutics, Inc.504 shares @ $16.95$9K